Tango Therapeutics Publishes Corporate Presentation on Vopimetostat PRMT5 Inhibitor Program in MTAP-Deleted Cancers

Reuters03-07

Tango <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Publishes Corporate Presentation on Vopimetostat PRMT5 Inhibitor Program in MTAP-Deleted Cancers

Tango Therapeutics Inc. released a corporate presentation outlining its oncology pipeline, including vopimetostat (TNG462), a PRMT5 inhibitor being studied in MTAP-deleted cancers. The company highlighted ongoing and planned clinical work in pancreatic and lung cancers, including a planned global randomized pivotal trial of vopimetostat monotherapy in second-line or later MTAP-deleted pancreatic cancer with progression-free survival and overall survival as co-primary endpoints. The presentation also described combination studies of vopimetostat with RAS inhibitors, including collaborations evaluating combinations with ERAS-0015, daraxonrasib, and zoldonrasib, with a safety and efficacy update planned for 2026. Tango also outlined additional programs including TNG456 in glioblastoma and TNG260 in lung cancer. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617630645?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-07 04:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617630645","market":"fut","top_or_hot":-1,"title":"Tango Therapeutics Publishes Corporate Presentation on Vopimetostat PRMT5 Inhibitor Program in MTAP-Deleted Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Publishes Corporate Presentation on Vopimetostat PRMT5 Inhibitor Program in MTAP-Deleted Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TNGX\">Tango Therapeutics Inc.</a> released a corporate presentation outlining its oncology pipeline, including vopimetostat (TNG462), a PRMT5 inhibitor being studied in MTAP-deleted cancers. The company highlighted ongoing and planned clinical work in pancreatic and lung cancers, including a planned global randomized pivotal trial of vopimetostat monotherapy in second-line or later MTAP-deleted pancreatic cancer with progression-free survival and overall survival as co-primary endpoints. The presentation also described combination studies of vopimetostat with RAS inhibitors, including collaborations evaluating combinations with ERAS-0015, daraxonrasib, and zoldonrasib, with a safety and efficacy update planned for 2026. Tango also outlined additional programs including TNG456 in glioblastoma and TNG260 in lung cancer. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tango Therapeutics Publishes Corporate Presentation on Vopimetostat PRMT5 Inhibitor Program in MTAP-Deleted Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTango Therapeutics Publishes Corporate Presentation on Vopimetostat PRMT5 Inhibitor Program in MTAP-Deleted Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-07 04:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tango <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Publishes Corporate Presentation on Vopimetostat PRMT5 Inhibitor Program in MTAP-Deleted Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/TNGX\">Tango Therapeutics Inc.</a> released a corporate presentation outlining its oncology pipeline, including vopimetostat (TNG462), a PRMT5 inhibitor being studied in MTAP-deleted cancers. The company highlighted ongoing and planned clinical work in pancreatic and lung cancers, including a planned global randomized pivotal trial of vopimetostat monotherapy in second-line or later MTAP-deleted pancreatic cancer with progression-free survival and overall survival as co-primary endpoints. The presentation also described combination studies of vopimetostat with RAS inhibitors, including collaborations evaluating combinations with ERAS-0015, daraxonrasib, and zoldonrasib, with a safety and efficacy update planned for 2026. Tango also outlined additional programs including TNG456 in glioblastoma and TNG260 in lung cancer. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNGX","symbol_name":"Tango Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL8mmlmD:1","article_id":"2617630645","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617630645","pubTimestamp":1772829253,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tango Therapeutics Inc. released a corporate presentation outlining its oncology pipeline, including vopimetostat , a PRMT5 inhibitor being studied in MTAP-deleted cancers. The company highlighted ongoing and planned clinical work in pancreatic and lung cancers, including a planned global randomized pivotal trial of vopimetostat monotherapy in second-line or later MTAP-deleted pancreatic cancer with progression-free survival and overall survival as co-primary endpoints. The presentation also described combination studies of vopimetostat with RAS inhibitors, including collaborations evaluating combinations with ERAS-0015, daraxonrasib, and zoldonrasib, with a safety and efficacy update planned for 2026. Tango also outlined additional programs including TNG456 in glioblastoma and TNG260 in lung cancer. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNGX":"Tango Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Tango Therapeutics发布了关于MTAP缺失癌症中Vopimetostat PRMT5抑制剂项目的公司演示文稿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNGX":0.9},"content_text":"Tango Therapeutics Publishes Corporate Presentation on Vopimetostat PRMT5 Inhibitor Program in MTAP-Deleted Cancers\n    \n\nTango Therapeutics Inc. released a corporate presentation outlining its oncology pipeline, including vopimetostat (TNG462), a PRMT5 inhibitor being studied in MTAP-deleted cancers. The company highlighted ongoing and planned clinical work in pancreatic and lung cancers, including a planned global randomized pivotal trial of vopimetostat monotherapy in second-line or later MTAP-deleted pancreatic cancer with progression-free survival and overall survival as co-primary endpoints. The presentation also described combination studies of vopimetostat with RAS inhibitors, including collaborations evaluating combinations with ERAS-0015, daraxonrasib, and zoldonrasib, with a safety and efficacy update planned for 2026. Tango also outlined additional programs including TNG456 in glioblastoma and TNG260 in lung cancer. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tango Therapeutics Inc. published the original content used to generate this news brief on March 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617630645","isCrawlerRequest":true}